Good day and welcome to the Weight Watchers third quarter 2026 earnings conference call. All participants will be in listen-only mode. Should you need assistance, please signal a conference specialist by pressing the star key followed by zero. After today's presentation, there will be an opportunity to ask questions. To ask a question, you may press star then one on your telephone keypad. To withdraw your question, please press star then two. Please note this event is being recorded. I would now like to turn the conference over to Ryan Wheeler, Director of Investor Relations. Please go ahead.

Thank you for joining us today for Weight Watchers' third quarter 2026 earnings conference call. Earlier this morning, we released the shareholder letter and press release with our third quarter 2026 results, which are available on the company's corporate website located at corporate.ww.com. The purpose of this call is to provide investors with some further details regarding the company's financial results as well as provide a general update on the company's progress. Reconciliations of non-GAAP measures disclosed on this conference call to the most directly comparable GAAP financial measures are available as part of the shareholder letter and press release. Before we begin, let me remind everyone that this call will contain forward-looking statements. Investors should be aware that any forward-looking statements are subject to various risks Thank you, Ryan. Good morning everyone.

Since this is my first earnings call as CEO, I want to share with you why I decided to join Weight Watchers team. It's very simple. I came here because I believe this company can win in a large and growing market. I spent most of my career in subscription and service businesses, and I know how important it is to earn and maintain members' trust, delivering value day after day and month after month. This is an incredible brand with a remarkable history. and few companies have had such a positive and meaningful impact on so many people's lives. Since joining Weight Watchers, I've made it my priority to spend time listening to our members, attending workshops, talking to our coaches, our registered dietitians, our clinicians and my colleagues. What has stood out for me is that we have an incredible team that cares deeply about our members and what we do every day. The Weight Loss journey is very personal. and the support people need changes significantly along the way. The weight loss industry is also evolving at an unprecedented pace. Today, access to GLP-1 medication is becoming increasingly commodified and new options are coming. With expanding market access, these medications are becoming more affordable and widely available to more people, including seniors through the Medicaid GLP-1 Bridge Program. As barrier to entry for GLP-1 prescriptions continue to decrease. A critical gap is emerging in the market, the acute need for ongoing guidance, including nutritional and behavioral support. We see the total addressable market growing, in part driven by the accessibility of GLP-1 medications. Whether you're on or off medication, people still need the support we provide. They still need to develop foundational habits that sustain healthy weight loss over a lifetime. That is why Weight Watchers has Three unique offerings, Core, Core Plus, and Med Plus, designed to support members wherever they are in their journey. And the results prove the value of our holistic approach. Weight Watchers Med Plus members who have prescribed GLP-1 medication and also regularly engaged in our GLP-1 success program are 29% more body weight on average at 12 months than those who did not engage with our structured behavioral support program. The benefits are long-term too. MedPlus members who engage with our behavioral support are able to achieve more than 20% weight loss on average after three years. Our science-backed behavioral support and human connection truly sets us apart. Our integrated platform is built to support members wherever they are on their journey, regardless of where they obtain their medication. Whether a member accesses clinicians trained to support people with obesity through our MedPlus offering or receive a prescription from their own healthcare provider, or through an online pharmacy, a GOP One success program provides the essential behavioral and community support they need. As anyone who's been on a waitlist journey can tell you, losing weight is not a straight line. Our members' needs change over time. No matter where they are on their path, we provide the support they need through our platform, our digital tools, and with both in-person and virtual workshops. We'll continue to bring together the best of science-backed behavioral support, clinical care, and Human Connections to support our members. The third quarter's results are evidence of the unique approach we take at Weight Watchers. Our members are responding to our high-value offerings. We increased clinical revenue 48% year-over-year, the largest year-over-year increase of any quarter in 2026. We achieved a four-straight-quarter sequential core-plus subscriber growth. And overall, we generated positive operating cash flow of $32 million. While we are laser-focused on this strategic evolution, we'll continue to be highly disciplined in our operations. The top-line progress in our high-value tiers, combined with careful expense management and disciplined marketing allocations, generated $51.7 million of adjusted EBITDA in the third quarter, representing a strong 33.8% margin. And with that, I'll turn it over to Felicia to discuss the financial results of the third quarter.

Good morning, and thank you, Stephen. Our third quarter results demonstrate continued progress in our higher value offerings. CorePlus and MedPlus now generate roughly half of our revenue. CorePlus subscribers grew sequentially for a fourth consecutive quarter, a milestone we have not achieved for 20 years, one we had to blow the dust off old filing cabinets to confirm. This higher value behavioral tier shows 16% growth in subscribers year over year. In addition, clinical subscription revenue has grown more than 30% year-over-year in every quarter this year, including 48% in the third quarter. Alongside this progress, we delivered $51.7 million of adjusted EBITDA, $15.1 million of positive net income, and $32.3 million of operating cash flow. I'm proud of this team's ongoing work and the continued progress made since our financial reorganization in June 2025. Now turning to subscribers, we ended the quarter with approximately 2.3 million total subscribers. Behavioral subscribers were approximately 2.1 million, down 26% year over year, with the decline concentrated in our core tier. Within behavioral, our core plus tier continues to gain share ending the quarter with 546,000 subscribers and now representing nearly a quarter of our total subscribers, up from 16% a year ago. Importantly, the number of Core Plus members enrolled in our GLP-1 Success Program has more than doubled since January, reinforcing the growing relevance of our structured behavioral approach as weight loss medications become more widely used. Clinical ended the quarter with 174,000 subscribers, up 40% year-over-year, and down from 197,000 at the end of June. As we expected in August, the sequential decline largely reflects the one-year mark of our transition off compounded semaglutides, with the 12-month plans introduced during that transition coming up for renewal in Q3 2026. Alongside that, the recalibration of our marketing spend across the portfolio also contributed. The deliberate recalibration of marketing spend across our portfolio has also supported two growing offerings, CorePlus and MedPlus, with differentiated ways to serve members using GLP-1 medications. Monthly subscription revenue per average subscriber, or ARPU, increased 14% year-over-year to $21. Reflecting the continued shifts in our subscriber mix toward higher value offerings. Within behavioral, Core Plus generates approximately twice the ARPU of Core and clinical ARPU of $68, roughly five times the value of Core. Turning to revenue, third quarter revenue was $152.9 million, down 11% from $172.1 million a year ago. Behavioral subscription revenue declined 22% to $113.9 million, primarily reflecting the smaller core subscriber base, partially offset by the growing contribution from Core Plus. Clinical subscription revenue increased 48% to $38 million and represented approximately 25% of total revenue compared with 15% a year ago. We continue to make progress on gross margins. Adjusted growth margin improves to 74.6%, our highest level of 2026. Importantly, this performance comes even as clinical, which has a higher cost of service, grew as the share of total revenue. Continued workflow automation and more efficient delivery of our services have contributed to our strong margin profile. Marketing expense was 33.1 million, or 21.6% of revenue, compared with $48.4 million, or 28.1% of revenue a year ago. Our investment to date in 2026 reflects deliberate timing and allocation across the portfolio. During Q1, our peak season marketing investment was more heavily concentrated in our MedPlus offerings to support the Wigobi pill launch, as well as included increased brand awareness to educate consumers of our MedPlus offerings. Q2 and Q3 included a more balanced allocation across our portfolio as we managed offerings with different maturities and margin profiles. Product development expense was $5.2 million, or 3.4% of revenue, compared with 4.4% a year ago, and adjusted selling general and administrative expense was approximately $25 million, or 16.4% of revenue, down from 17.8%, reflecting continued cost discipline. We generated positive net income of $15.1 million, our first two consecutive quarters of positive net income since emergence. Adjusted EBITDA increased 21% to $51.7 million, and adjusted EBITDA margin increased to 33.8% compared with 24.9% in Q3 2025. This performance reflects the operating improvements we have made and the deliberate timing and allocation of marketing investments. Net income also benefited from lower depreciation and amortization and lower interest expense following our second quarter debt reduction. Now turning to liquidity, we ended September with 126.4 million of cash and cash equivalents of approximately 25 million from the end of June. We generated 32.3 million of operating cash flow during the quarter after 11.4 million in interest payments on our term loan and invested approximately 7 million in capitalized software and website development. Following our financial reorganization in June 2025, we have reduced total debt by more than 70% from approximately 1.6 billion to 423.6 million. This stronger financial position supports continued strategic investment in the business while maintaining financial flexibility. Turning to our full year outlook, we are narrowing our 2026 guidance ranges. We now expect revenue of $625 million to $630 million compared with our previous range of $620 million to $635 million. An adjusted EBITDA of $110 million to $115 million compared with our previous range of $105 million to $115 million. We expect clinical subscription revenues to represent approximately 25% of full-year revenue compared with approximately 16% in 2025. Our outlook continues to incorporate moderate sequential clinical subscriber declines in Q4 at a lower level relative to Q3, as Q4 does not include a comparable group of 12-month plans coming up for renewal. Looking beyond the fourth quarter, we see a meaningful opportunity to grow awareness of our MedPlus offerings. Our concentrated clinical investment in Q1 2026 raised awareness, but those gains did not carry through the year as we had anticipated. We are building a more diversified marketing approach that provides us additional ways to reach prospective members. We continue to expect year-over-year growth in CorePlus subscribers. We now expect full-year adjusted gross margin to be approximately 74% compared to the prior expectation of above 72%, representing a modest decline relative to 2025. Driven by the change in revenue mix, partially offset by increased workflow automation and more efficient delivery of services. We continue to expect 2026 marketing expenses as a percentage of revenue to increase modestly compared to 2025. We expect to increase spend modestly in Q4 compared to Q3 as we prepare for peak season to keep second half investment below first half levels while continuing to allocate our spend across the portfolio of product offerings. With that cadence, we expect second half adjusted EBITDA in 2026 to be higher than the second half of 2025. We also continue to expect positive operating cash flow for full year 2026 including projected interest costs of approximately $45 million to $50 million. Our third quarter results continue to demonstrate the earnings power of a more disciplined operating model and our members' growing interest in higher value offerings. As Core Plus and Med Plus offerings become a larger share of our business, we see a company being built with a much stronger and more robust financial foundation. With that, handing back to Stephen for some closing comments.

Thanks, Felicia, for the update. Let me close by saying we have an incredibly strong team and a foundation to build upon. But we have more to do. I will be very clear. I believe this business is not looking up to its potential. My focus is on serving every one of our members across Core, Core Plus, and Med Plus. We'll strengthen their experience, improve our products and applications, and demonstrate the uniqueness We will now begin the question and answer session. To ask a question, you may press star then one on your telephone keypad. If you're using a speakerphone, please pick up your handset before pressing the keys.

If at any time your question has been addressed and you would like to withdraw your question, please press star then 2. At this time, we will pause momentarily to assemble our roster. The first question today comes from Alex Fehrman with Lucid Capital Markets. Please go ahead.

Hey, guys. Thanks very much for taking my question. Steven, nice to meet you on the call here. You wanted to ask about what appears to now be a pretty sustained turnaround in Core Plus, now getting back to four quarters of growth. That's now a pretty meaningful share of your membership. Can you give us a little bit more color on what's driving that and how sustainable it is? Is this basically you're doing a better job Converting Your Stickier Behavioral Members to the Higher Price Offering? Or is this more about new members coming into the funnel, getting them to that $20 a month offering instead of the $10 one? And then, sorry to keep tacking them on here, but all on this topic of Core Plus, I think, Felicia, you mentioned there is pretty significant growth within Core Plus of people using the GLP-1 companion offering. Is it fair to say that a good chunk of this growth in CorePlus is people that are taking GLP-1s somewhere other than the Weight Watchers platform?

Yeah, so Alex, again, nice to meet you. Thank you for the question. Let me start, and then the specifics, I'll hand it back to Felicia. But I think underneath all of this is we have an incredible brand, you know, and our proposition and our point of differentiation is around support. And I think that's demonstrated through CorePlus, but also through MedPlus as well. And I really think we have the platform that supports our members where they are in the journey, you know, whether it's on the behavioral side, whether it's clinical care, nutrition, it's the support that we offer through our virtual and in-person workshops that I think really sets us apart both on core class but also on med class. And so on the specific trends underneath that, I'll hand it over to Felicia and she can comment more about that.

And we do appreciate the question, Alex. We are very excited about the consecutive quarter over quarter growth that we are showing in Core Plus. And I would say it's all of the above. And so the adoption of GLP-1 Success Program has more than doubled since the start of the year. And so that has been an important driver. As we've previously discussed, we are adopting new ways to engage with our community. And so 40% more Core Plus members participate in our virtual experiences as well. And so that has been an important part. And we are very excited about the overall subscriber growth this quarter, showing approximately 16 percent and having that accelerate as we've moved through this year. I would also add that the member migration has continued to also be a positive with Core Plus with approximately 20 percent of the members or percentage of signups coming from coming from core members as well.

Okay, that's really helpful. Thank you both for that. And then I could ask about gross margin as well. Intuitively, I would think that, you know, there's going to be some gross margin pressure over time as the clinical offering continues to grow as a share of your total revenues. Obviously, with today's news, you're taking the gross margin target up a little bit for the year. Is that due to the growth in Core Plus? Is it, you know, likely that that could be an offset in terms of gross margin to the growth in clinical. Just trying to understand how we should think about that over the next few years.

We're excited about all of the work that John Volkmann and his team have done in allowing for the execution of costs to be more efficient without forgoing on any of the services that we provide to our members. And so as we mentioned, we do anticipate that being approximately 74%. Last year was also at approximately 74%, so holding it fairly flat year over year has been a very exciting part of our trajectory. And that has been with our two offerings, Core Plus and Med Plus, significantly increasing as a percentage of total. And so with Med Plus going from approximately 15% of our revenue in 2025 to us now expecting it to be at approximately 25% of our revenue in 2026. I think that's an important factor in the fact that we have been able to maintain all the margins. And then also, as it relates to the expansion of our core plus offering, that went from approximately 18% of our subscriber count to almost 25% of our subscriber count this quarter as well.

And Alex, I'll just add to Felicia's comment. As we look forward, it's really about operating discipline. And as we look at how we scale a business, and as I said in my opening remarks, it's really about profitable growth. That's what we're focused on. And so we are looking at how to grow this business profitably as well as scaling it up, but maintaining the operating discipline that the team has in place today and looking at where we can take technology and apply that even more as we scale a business as we go forward.

That's great. Well, thank you. Thank you both for those thorough answers. Appreciate it.

The next question comes from Nathan Feather with Morgan Stanley. Please go ahead.

Hey, everyone. Thanks for the question, and nice to meet you, Stephen. First, on the clinic side, you did see at least monosequential declines there. I can't decompose how much of that was the lapping of the one-year compounded plans versus kind of underlying change. and then just given the results we've seen this year, should you now expect clinic will have a more similar seasonality to the behavioral business with the one QP and then some slow attrition as you go through the remainder of the year?

I would say to just answer the second part of your question first. I mean, it's hard to tell whether the seasonality of clinic at this point is going to look similar to the behavioral business because we did have the WacoVita launch in Q1 of 26. With that being said, as we think about the decline from Q2 to Q3, I would say a couple of factors contributed as we anticipated. The most material of the factors is that Q3 2026 is a higher churn quarter as we are lapping the introduction of the 12 months long term commitment plans that we introduced in Q3 of 2025. as we had rolled off our compounded semaglutide offering at that point. We had also noted that this and Q3 is anticipated and will be our lowest marketing spend for the year. However, we do anticipate still to show a modest increase year over year in marketing as a percentage of total revenue. The other thing that I would note is that we did recalibrate across the portfolio, and we plan to continue to calibrate our marketing across the portfolio because we do have multiple touchpoints with GLP-1. And so whether a member is getting their meds with or without us, we do want to make sure that we are taking advantage of the larger TAM of the GLP-1 market across both our MedSUS and our CorePlus offerings.

Yeah, and as we look ahead, we're going to be continuing to focus on refining our initial clinical intake Thank you for joining us today. and the process. And even looking beyond medication, you know, we're going to be looking at ways to improve front-end guidance to help members choose the commitment duration that best fits their specific clinical timeline and goals. And then through all of that, looking to connect touchpoints across clinicians, registered dieticians and behavioral tools. So it's really helps support members seamlessly at every stage from titration to long-term maintenance.

Yeah, and Nathan, thanks for the question. Good to meet you as well. I think, you know, as John said, really about looking at the pain points in every customer journey. So whether you're a core customer, a core plus, or a MedPlus customer, it's really about addressing those friction points, and that's what we're looking at, and how do we enhance the member experience throughout the journey. So we're looking at how do we lower churn, how do we maintain longer lifetime value for our customers, and that's a focus of the business going forward as well. But I also want to emphasize the point that Felicia and John touched on, which is MedPlus is one way that we support customers with GLP. And so, you know, access to GOP1 medications becomes more commoditized and access to prescriptions is not really a barrier. You know, we're really focused on how do we support customers irrespective of which journey they're on and where they get the medication from. So, you know, I really look at the support of the underlying differentiator that supports customers on MedPlus as well as on the Core Plus business as well.

Okay, great. That is very helpful. And then, Stephen, as you've come in and been able to kind of take a look at the business, where do you see the biggest opportunities to, whether it's drive growth, improve costs, and kind of how should we think about your early priorities, especially as we head into peak season in the next few months?

Yeah, no, I appreciate the question, Nathan. I think, look, as I come in, I mean, one thing that's struck me, and I made this point in my opening remarks, I made it a priority to spend time with our members, our coaches, and the team And look, it's just incredible to me the passion our team has to support our members. People deeply care about our mission and our objective, what we're trying to do, and that's staggering. And also the feedback from our members has just been phenomenal. I mean, we touch almost 1.5 million members throughout virtual and in-person workshops those last eight weeks and so it's amazing to me sort of how deeply we impact people's lives and the positive impact we have so that's the first thing I take away you know in the weeks that I've been here but what's really important for us is the support we provide and that's what really sets us apart in the industry and I think it really puts us in a very strong position given our brand But what's exciting, and this goes to Felicia's earlier comment about the TAM, the TAM process is getting bigger. GOP-1s is just fueling that addressable market for us, and that's what I see. And as I said, irrespective of where you get your medication from, whether it's coming and we support you through MedPlus or whether you're getting it from somewhere else, We've got a program for those people, and the data proves that it works. And again, I cited that in my prepared remarks, that people lose more weight when they combine support together with medication, and you can also help them keep it off over a period of time as well, which is fantastic. So I'm thrilled to be here. I think we have an incredible brand team that cares very deeply about what we're doing. And look, what I'm here to do is bring focus. Let's execute against that and have operating discipline and fiscal discipline as we go forward. Thank you very much.

The next question comes from Owen Ricker from Northland Capital Markets. Please go ahead.

Hey, guys. Thanks a ton for taking my questions. And nice to meet you, Steven. First for me, EBITDA was pretty impressive. It beat us by quite a bit this quarter. I guess how much of that beat was timing maybe that lower marketing pulled forward versus durable structural improvements?

Sure. So overall, we have been making changes to our execution of costs across cost of sales as well as product and tech and adjusted selling general and administrative expenses. And you are seeing that come through the Q3 2026 numbers. And that is also why we feel confident narrowing our adjusted EBITDA range in terms of guidance towards the high end. of our previously disclosed guidance. I would say though, as we gear up for the upcoming 2027 peak season, not dissimilar to previous years, there will be a step up in marketing spend from Q3 to Q4. And that is one of the reasons for the guidance that we're providing on the full year.

Got it, got it. Super helpful. And then second for me, There are some partnership announcements recently, you know, Google Health, Sam's Club, Lilly Direct. Anything to call out on how those might be performing? I know it's super early, but any color there would be helpful.

Yeah, thanks for the question. Also, good to meet you. It's a little too early for us to comment specifically about any one of those partnerships, but I do want to sort of emphasize the importance of those partnerships and additional partnerships that we're exploring because as we look at how do we meet our members and where they are, we want to meet them where they are through the channel that's most effective. and also gets into how we look at our marketing investment and how do we optimize that in order to make sure that it's efficient but also effective in terms of the return on investment we're putting in there. So our partners are important, but it is too early today to call out specific metrics. But as we go forward, we'll be updating that as we make more progress there. Got it. Thanks for time.

The next question comes from Justin Ages with CJS Securities. Please go ahead.

Hi, morning all, and nice to meet you, Stephen. My first question, you know, you've had a couple nice quarters now of solid free cash flow. So first, can you just remind us of the cash sweep? And then, you know, where do you see your priorities in using that cash? Obviously, you know, beyond marketing expenses, where you look to pay down debt first.

Yeah, so just as a reminder, the cash suite is calculated on the last 10 days of the first quarter, and then it is paid on the anniversary of the financial reorganization, which would be at the end of June of that quarter. And so overall, what you can see is we've been very deliberate in terms of our timing as well as our allocation of capital and managing both the debt and, you know, the return to growth for Weight Watchers. And we will continue to do so. You saw us last quarter be opportunistic as it related to the debt. And so as we work through and continue to work through 2027 planning and things like that, if we do see an opportunity to further pay down the debt or to invest, those will be areas that we will continuously evaluate.

Thank you for that, Felicia. And then you've invested quite a bit in the new app. Just wanted to know what the feedback you're getting there is, if that's contributing to and more sticky subscribers, as well as a comment on some of the past strategic initiatives like the menopause initiative and then how that's helping drive subscribers.

Yeah, so I think it's nice to meet Justin and then I'll start and then sort of hand it to the team on sort of the specifics as it relates to kind of the product. What we're really focused on is how do we enhance the quality and the depth of support we're providing for each customer wherever they are in their journey. And so think of it as how do we bring more value to our membership? And that's the one thing I've frankly really enjoyed over the last several weeks is talking to members about how meaningful our products are and what we're doing to enhance that experience and that's really a focus for us. So we're looking at how do we enhance the product, the application, how do we add new features, new capabilities in order to make that a much better experience and maintain that relationship over the lifetime. And we're also looking at how do we take some of that Thank you for joining us today. and specifically the products of Infected Felicia.

So just as Stephen mentioned, in terms of taking the in-person virtual experiences and bringing them virtually, the other thing that we did this past year is upleveled our structured behavioral support. And there are two programs that are included in our core plus offering, the GLP-1 Success Program that we discussed and also our menopause offering. And so both have been fantastic in being part of the growth of our core plus subscriber count.

Yeah, and one other thing I'll add, Justin, I think which is also very interesting as we look forward into 27 is the Medicaid Bridge Program. and so we also brought that in as well in terms of being able to support that for seniors as they go forward. So I don't know, John, if you wanna touch on that program and what we do in there as well.

Yeah, yeah, we were really excited about the launch of the Medicare Bridge program. Obviously this opens up coverage for a substantial population of folks We can also serve them through our core plus tier VR. and a lot of the industry data indicating that the, you know, the overwhelming majority, the vast majority of interest is coming from individuals who are completely new to GLT1s. And, you know, this really, you know, confirms that the program is expanding the overall marketplace. So, you know, looking ahead, our focus is going to be on expanding awareness among eligible seniors so that They know that Weight Watchers is their go-to partner for both weight health support as well as comprehensive clinical care.

That's great. I appreciate the thorough answer. Thank you.

This concludes our question and answer session. I would like to turn the conference back over to Stephen Bai for any closing remarks.

Yeah, look, this is my first time in school and I really appreciate the interest in white watches and the business. You know, I just want to reiterate, you know, this business is an incredible business with an amazing brand with people that care deeply about the product and the services we offer and the support we offer to our members. And so I'm thrilled to be here. I'm excited about the future of the business. The team is very focused on what we need to achieve in terms of returning this business back to profitability in 27. And I look forward to providing updates as we go forward in upcoming earnings calls and other events that we have. So thank you very much for your interest in the company and look forward to engaging with the investor base as we go forward.

The conference has now concluded. Thank you for attending today's presentation. You may now disconnect.